Disappointing Preliminary Earnings from Quest Diagnostics Trickles Down to Qiagen

ISI analyst Vijay Kumar reported Qiagen N. V.

may have repercussions from reimbursements from coding changes issues. Qiagen short interest rose to a 2-Year high before the third quarter. Kumar noted that Quest Diagnostics Inc.

preliminary earnings are taking a hit due to increased diagnostic coverage denial, missing 3Q estimates. This hit may hurt Qiagen despite the fact that shares are currently up 0.19% today. QGEN is underperforming the broader averages missing the percent and a half with the rest of the market. Qiagen closed at $20.80 on Wednesday. Quest closed at $61.70 and is currently trading at -4.72%.